News › Industry News, News

Breaking Business News: Allergan Acquires Bonti

September 18, 2018

Allergan acquired Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications.
Following completion of the acquisition, Allergan will obtain global rights to Bonti’s pipeline consisting of two botulinum neurotoxin serotype E (BoNT/E) programs currently in Phase 2 development, EB-001A (aesthetic) and EB-001T (therapeutic).
Read more at DermWire >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • 10 Marketing Truths Every Aesthetic Practice Needs to Hear Right Now
    • AI, FDA, PDGF: The Talk of MSS
    • Radiologists Warn that Décolletage Filler May Interfere with Breast Cancer Screening
    • The Beauty Health Company (SKIN) Rebrands to SkinHealth Systems
    • Amazon Launches GLP-1 Weight Loss Program with One Medical